Presentation at the European Society for Medical Oncology Congress 2022 (September 11, 2022; Paris, France): Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)
Propella Therapeutics, Inc. presented phase 1/2 data of PRL-02 (a long-acting IM depot injection of abiraterone decanoate) for the treatment of advanced prostate cancer at the European Society for Medical Oncology Congress 2022 in Paris, France on September 11, 2022.
